Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Experts at Oxford are teaming up with leading figures from industry to advance development of a gene therapy for cystic fibrosis.

DNA sequence in colour © Shutterstock

The UK Cystic Fibrosis Gene Therapy Consortium, of which the University is a member, will join with Boehringer Ingelheim and Oxford Biomedica to develop a new viral vector-based therapy.

The partnership builds on pioneering research carried out by the Consortium including clinical trials, which have shown encouraging results.

Read more